Eli Lilly reports better-than-expected quarterly sales, driven by demand for its newer treatments for diabetes and cancer. » Read More
Citron's Andrew Left says he does not think Valeant shares will trade above $60 anytime soon.
Capsule says its home-delivery prescription service will be faster and simpler for many consumers.
Employers around the country say they are struggling to find workers who can pass a pre-employment drug test, The New York Times reports.
Valeant said on Monday it would make available to all hospitals in the U.S. an enhanced rebate program to reduce the price of Nitropress and Isuprel.
Pfizer announces it is buying drugmaker Anacor Pharmaceuticals for $99.25 per share in cash.
Intrexon is ready to fight the Zika virus and believes it will get approval to do so in the U.S., its CEO says.
Allergan rose nearly 3 percent after Goldman Sachs released a very bullish note on the stock.
Lars Sorensen, CEO of Novo Nordisk, shares what he thinks of a potential Brexit by the U.K. in next month's referendum and how it would hit the currency.
There is still no cure for the Zika virus, travelers can only be extremely cautious when in Brazil, says Mundipharama Asia Pacific's Raman Singh.
CNBC's Meg Tirrell reports on Valeant possibly not living up to its promise to offer discounts on some drugs.
David Amsellem of Piper Jaffray discusses a report that hospitals are still waiting on Valeant's promised drug discounts.
The study said when people took acetaminophen, Tylenol's main ingredient, they were less likely to empathize with people experiencing pain. The USAToday reports.
The company's COO is departing as its flagship laboratory operations are threatened with sanctions, The New York Times reports.
Hedge fund manager Bill Ackman is parting company with the man who introduced him to his bad investment in Valeant Pharmaceuticals.
A judge has unsealed records from a Kentucky lawsuit against the maker of the prescription painkiller OxyContin.
There is also strong opposition to speeding up the federal drug approval process, a new poll finds.
These professors point out some "glaring errors" in the attack on Bernie Sanders' single-payer health plan.
Allergan reported a 48 percent rise in quarterly revenue, led by a strong performance by its branded drugs business.
Valeant said on Monday it expects to file its first-quarter report with the regulators on or before June 10, ahead of the July 31 deadline.
A new home conception kit offers health insurers a less expensive alternative to pricey fertility treatments.
Get the best of CNBC in your inbox